Fig. 2

miR-424 is downregulated in ovarian cancer and specifically binds to MYB. a The expression of MYB in ovarian cancer tissues and adjacent ovarian epithelium tissues examined by immunohistochemistry (scale bar = 25 μm), adjacent ovarian epithelium tissues n = 43, ovarian cancer tissues n = 85. b The mRNA expression of MYB in ovarian cancer tissues and adjacent ovarian epithelium tissues detected by RT-qPCR; *p < 0.05. c The protein expression of MYB in ovarian cancer tissues and adjacent ovarian epithelium tissues examined by Western blot analysis. d The expression of MYB in normal human ovarian epithelial cell line HOSEpiC and ovarian cancer cell lines (SKOV-3, HO8910, A2780) detected by RT-qPCR. e The survival rate of ovarian cancer patients with higher MYB expression analyzed by Kaplan–Meier survival analysis. f The expression of miR-424 in ovarian cancer tissues and adjacent ovarian epithelium tissues detected by RT-qPCR; *p < 0.05. g The correlation between MYB and miR-424. h The binding site between miR-424 and MYB predicted using an online data base. i The fluorescence activity determined by dual-luciferase reporter gene assay. j The mRNA expression of MYB in cells after treatments with miR-424 mimic or inhibitor detected by RT-qPCR. k The protein expression of MYB in cells after treatments with miR-424 mimic or inhibitor examined by Western blot analysis; *p < 0.05 compared with cells treated with mimic-NC, ^#p < 0.05 compared with cells treated with inhibitor-NC. All data above were measurement data and were presented as mean ± standard deviation. A comparison between tumor tissues and adjacent ovarian epithelium tissues was conducted using a paired t-test, and data comparison between two groups was performed using the unpaired t-test. Data among multiple groups were compared by one-way ANOVA, and Pearson correlation analysis was used to analyze the correlation between miR-424 and MYB. All experiments were repeated 3 times independently